Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 7063-7070

  Hamblett, Kevin J ^a   Senter, Peter D ^a   Chace, Dana F ^a   Sun, Michael M C ^a   Lenox, Joel ^a   Cerveny, Charles G ^a   Kissler, Kim M ^a   Bernhardt, Starr X ^a   Kopcha, Anastasia K ^a   Zabinski, Roger F ^a   Meyer, Damon L ^a   Francisco, Joseph A ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CD30 ANTIGEN; MONOCLONAL ANTIBODY; MONOMETHYL AURISTATIN E MONOCLONAL ANTIBODY CAC10 CONJUGATE; MONOMETHYL AURISTATIN E2 MONOCLONAL ANTIBODY CAC10 CONJUGATE; MONOMETHYL AURISTATIN E4 MONOCLONAL ANTIBIDY CAC10 CONJUGATE; MONOMETHYL AURISTATIN E8 MONOCLONAL ANTIBODY CAC10 CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL; MAXIMUM TOLERATED DOSE; MICE; OLIGOPEPTIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 6044223544     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0789     Document Type: Article

References (30)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1(2):118-29.
2. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277(30):26733-40.
3. Shinkawa T, Nakamura K, Yamane N et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278(5):3466-73.
4. Pastan I, Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Investig Drugs 2002;3(7):1089-91.
5. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43(11):1507-29.
6. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003;101(2):391-8.
7. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 2000;18(11):2282-92.
8. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19(13):3244-54.
9. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21(2):211-22.
10. Brass PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7(6):1490-6.
11. Chan SY, Gordon AN, Coleman RE, et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 2003;52(4):243-8.
12. Doronina SO, Toki BE, Torgov MY, et al. Development of potent and highly efficacious monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21(7):778-84.
13. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65.
14. Chari RV, Jackel KA, Bourret LA, et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 1995;55(18):4079-84.
15. Meyer DL, Senter PD. Recent advances in antibody drug conjugates for cancer therapy, Chp 23. Annu Rep Med Chem 2003;38:229-37.
16. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52(1):127-31.
17. Dubowchik GM, Firestone RA, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 2002;13(4):855-69.
18. Hamann PR, Hinman LM, Hollander T, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13(1):47-58.
19. Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody- calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002;13(1):40-6.
20. King HD, Yurgaitis D, Willner D, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjug Chem 1999;10(2):279-88.
21. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (Lond.) 1982;299(5878):65-7.
22. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66(4):848-58.
23. Gerdes J, Schwarting R, Stein H. High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. J Clin Pathol (Lond.) 1986;39(9):993-7.
24. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10(6):457-70.
25. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62(13):3736-42.
26. Firestone RA, Willner D, Hofstead SJ, et al. Synthesis and antitumor activity of the immunoconjugate BR96-Dox. J Control Release 1996;39:251-9.
27. Willner D, Trail PA, Hofstead SJ, et al. (6-Maleimidocaproyl)hydrazone of doxorubicin: a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 1993;4(6):521-7.
28. Schroeder DD, Tankersley DL, Lundblad JL. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction. Vox Sang 1981;40(6):373-82.
29. Osborn BL, Olsen HS, Nardelli, B et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303(2):540-8.
30. Emerson DL, Bendele R, Brown E, et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 2000;6(7):2903-12.